Article

WaveLight attains 20% of U.S. refractive laser sales in 1 year

New Orleans-WaveLight Inc. announced that during the last 12 months, its Allegretto Wave laser achieved a 20% share of all new refractive laser sales in the United States.

"We consider our success in the U.S. market to be our greatest accomplishment to date," said Max Reindl, chief executive officer of WaveLight Laser Technologie AG. "Ophthalmologists and patients alike benefit from the Allegretto Wave's shorter treatment times, safety features, and unique ablation profile designed to minimize the induction of spherical aberrations during surgery. Strong demand for the Allegretto Wave validates our commitment to develop and introduce the most innovative technology in the marketplace."

In addition to acquiring a considerable presence within ophthalmology, WaveLight recently announced that its revenues have increased 30% for the fiscal year ending July 31, 2004. WaveLight attributes much of its financial performance to refractive laser sales.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
1 expert is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
© 2025 MJH Life Sciences

All rights reserved.